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Abstract
Background: Prion diseases are caused by the accumulation of an aberrantly folded isoform of
the prion protein, designated PrPSc. In a cell-based assay, quinacrine inhibits the conversion of
normal host prion protein (PrPC) to PrPSc at a half-maximal concentration of 300 nM. While these
data suggest that quinacrine may be beneficial in the treatment of prion disease, its penetration into
brain tissue has not been extensively studied. If quinacrine penetrates brain tissue in concentrations
exceeding that demonstrated for in vitro inhibition of PrPSc, it may be useful in the treatment of
prion disease.
Methods: Oral quinacrine at doses of 37.5 mg/kg/D and 75 mg/kg/D was administered to mice for
4 consecutive weeks. Plasma and tissue (brain, liver, spleen) samples were taken over 8 weeks: 4
weeks with treatment, and 4 weeks after treatment ended.
Results:  Quinacrine was demonstrated to penetrate rapidly into brain tissue, achieving
concentrations up to 1500 ng/g, which is several-fold greater than that demonstrated to inhibit
formation of PrPSc in cell culture. Particularly extensive distribution was observed in spleen
(maximum of 100 µg/g) and liver (maximum of 400 µg/g) tissue.
Conclusions:  The documented extensive brain tissue penetration is encouraging suggesting
quinacrine might be useful in the treatment of prion disease. However, further clarification of the
distribution of both intracellular and extracellular unbound quinacrine is needed. The relative
importance of free quinacrine in these compartments upon the conversion of normal host prion
protein (PrPC) to PrPSc will be critical toward its potential benefit.
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Background
Prion diseases, while rare, invariably result in fatal neuro-
degeneration. At present, no therapy has been proven to
be useful in the treatment of prion disease. However, acri-
dine and phenothiazine derivatives have been evaluated
[1,2] using an in vitro model, and quinacrine and chlo-
rpromazine inhibit PrPSc formation in a scrapie-infected
neuroblastoma (ScN2a) cell line [2]. Half-maximal inhi-
bition of PrPSc  formation at effective concentrations
(EC50) for quinacrine was found to be 300 nM (120 µg/
ml) [2]. While this concentration represents the concen-
tration of quinacrine added to the cell culture, it does not
reflect the effective intracellular quinacrine concentra-
tions. In the past, quinacrine was used as an antiparasitic
agent in the treatment of malaria and giardiasis, however,
more effective, less toxic agents have since replaced this
agent [3]. While quinacrine may be useful in the treat-
ment of prion disease, its pharmacokinetics have not been
extensively studied. Studies from the 1940s suggest that
quinacrine is associated with extensive tissue distribution
and a prolonged pharmacologic half-life [3,4]. However,
the rate and extent of quinacrine penetration into brain
tissue has not been characterized. If quinacrine adminis-
tration  in vivo results in brain tissue concentrations
exceeding that shown to inhibit PrPSc in vitro, it may con-
stitute an effective therapy for prion disease. While the
precise site of antiprion action is unknown (intracellular
versus extracellular) adequate quinacrine penetration into
brain tissue might result in an effective agent for the treat-
ment of prion diseases.
The objective of this study was to characterize the achiev-
able plasma concentrations and associated tissue (brain,
liver, spleen) penetration associated with quinacrine.
Methods
Animal Model
The protocol was approved by the institutional animal
care and use committee. The Animal Facility of the Insti-
tute for Neurodegenerative Diseases provided animal
samples from 2 different strains of mice, FVB and CD1.
Twenty four animals of each strain (24 FVB and 24 CD1
strain animals) were fed 37.5 mg/kg/D and 24 animals of
each strain were fed 75 mg/kg/D of oral quinacrine over a
4-week period (weeks 1–4), given ad lib as a chocolate fla-
vored liquid diet. From weeks 5–8 animals were given reg-
ular feed without quinacrine. At weekly intervals, 3
animals of each strain were euthanized and tissues were
collected for analysis.
Quinacrine level analysis
Preparation of standard solutions
Quinacrine dihydrochloride (purity: 98.6%) was pur-
chased from Fluka, while sulfadimethoxine sodium salt
(purity: 98%) which served as the internal standard (IS)
was obtained from Sigma. Quinacrine stock solution was
prepared as 1 mg/ml in methanol. Sulfadimethoxine
stock solution was prepared as 1 mg/ml in 50% methanol.
The working solutions were prepared by diluting the
respective standard and control stock solutions with 50%
methanol and 0.1% formic acid to 2 µg/ml and 100 ng/
ml, respectively. All solutions were stored in a 4°C refrig-
erator in silinized brown glass containers.
LC/MS/MS system and conditions
The HPLC system employed a Shimadzu LC-10 AD pump
and a Waters intelligent Sample Processor 717 Plus
autosampler/injector. A BDS Hypersil C18 column, 50 ×
4.60 mm, 5 µm particle size was directly coupled to a
Micromass Quattro LC Ultima triple quadrupole tandem
mass spectrometer using electrospray ionization in posi-
tive ion mode. The sample cone voltage and collision
energy were 25 V and 20 eV respectively for both quina-
crine and the internal standard and the source block and
desolvation temperature were 100°C and 400°C, respec-
tively. The mass scanning mode employed multiple reac-
tion monitoring (MRM) with the singly charged
quinacrine ion selected at m/z 400.5 giving a fragment ion
at m/z/142.0, and the internal standard at m/z
311.0→156.0. The mobile phase consisted of CH3OH/
H2O/TFA (45:55:0.05) with 1 mM ammonium formate.
The flow rate was 0.8 ml/min with 1/4 split into the mass
spectrometer. The injection volume was 5–10 µl with a
run time of 3.5 min.
Sample preparation
All samples were stored at -70°C until analyzed. Each tis-
sue sample was subjected to a specific method, as
described below, for drug extraction and for the determi-
nation of concentration. All samples were analyzed by LC/
MS/MS.
Accuracy and precision
Accuracy and precision was demonstrated throughout the
working range with interday and intraday coefficient of
variation and relative error <10%.
Plasma extraction
Each plasma sample was thawed at room temperature for
10–15 min; then 20 µl of plasma was aliquotted to a new
test tube. To each tube 200 µl of 70% acetonitrile solu-
tion, containing 0.1% formic acid and 50 ng/mL of inter-
nal standard, was added. The test tubes were vortexed at
high speed for 1 min and centrifuged at 10,000 rpm for 10
min. The supernatant was transferred into the autosam-
pler for LC/MS/MS analysis. A set of standard curves with
a duplicate set of quality control (QC) samples was gener-
ated for sample analysis.BMC Infectious Diseases 2004, 4:53 http://www.biomedcentral.com/1471-2334/4/53
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Brain samples
Prior to the in vivo study, the stability of quinacrine in
mouse brain tissue was determined. Using 3 different
doses of quinacrine (4 mg/kg/d, 80 mg/kg/d, 160 mg/kg/
d), mouse brain tissue was soaked in 100% methanol for
7 days. Samples were taken on days 0,1,2,3, and 7 to ana-
lyze quinacrine concentrations using LC/MS/MS. Com-
plete equilibration was observed by Day 1 and no
degradation in quinacrine was noted through day 7.
Brain samples were thawed (in plastic tubes) at room tem-
perature for 15–20 min and weighed. To each sample 0.5
ml of 0.9% NaCl was added followed by incubation at
room temperature for 1 h. For the standard curve and
quality control samples, a brain tissue sample from an
untreated mouse was spiked with different amounts of
quinacrine and incubated at room temperature for 1 h.
After the addition of 100 µl of 1 µg/ml internal standard
solution in 50% methanol and 0.1% formic acid, 5 ml of
100% methanol was added into each sample and soaked
at 4°C for two weeks. On the last day, 200 µl was aliquot-
ted from each brain sample and placed into the autosam-
pler for analysis via LC/MS/MS.
Q1 and Q3 mass spectra of quinacrine Figure 1
Q1 and Q3 mass spectra of quinacrine
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Liver samples
Liver samples were thawed at room temperature for 15–
30 min and weighed. Considering the increased size of the
liver samples and that the increased connective tissue in
liver samples could potentially prevent the complete dis-
tribution of quinacrine into methanol, homogenization
was used for these samples. To each sample 100% metha-
nol was added (10 ml/g of tissue) and the tissue was
homogenized in ice water for 1 min at speed 3 (Tissue
Tearor, model 985-370, Biospec Products, Inc). The inter-
nal standard (100 µl of 10 µg/ml in 50% methanol, 0.1%
formic acid) was added to 0.2 ml of each homogenized
liver sample in a glass test tube. Samples were vortexed for
1 min, centrifuged at 3000 rpm for 10 min and 20 µl of
each supernatant was transferred into a new test tube.
Each sample was further diluted with 4 ml of 50% meth-
anol, vortexed, and 200 µl was transferred to the autosam-
pler for LC/MS/MS analysis. A set of standard curve with a
duplicate set of QC samples was generated for sample
analysis.
Spleen samples
Spleen sample preparation was similar to the preparation
of brain samples using a methanol soak. Prior to the in
vivo study, the stability of quinacrine in mouse spleen tis-
sue was determined. Using 3 different doses of quinacrine
(4 mg/kg/d, 80 mg/kg/d, 160 mg/kg/d), mouse spleen tis-
sue was soaked in 100% methanol for 7 days. Samples
were taken on days 0, 1, 2, 3, and 7 to analyze quinacrine
concentrations using LC/MS/MS. Complete equilibration
took place by Day 1 and no degradation in quinacrine was
observed through day 7.
Samples from the in vivo analysis were soaked for 14 days
at 4°C. On day 14, 50 µl was aliquotted from each spleen
sample and diluted with 1 ml of 50% methanol. Each
sample was vortexed for 1 min and 200 µl was transferred
to the autosampler for LC/MS/MS analysis. A set of stand-
ard curves with a duplicate set of QC samples was gener-
ated for sample analysis.
Results
Quinacrine analysis
The mass spectrum of quinacrine (Q1) and its tandem
spectrum (Q3), showing the fragment ion selected for
MRM, are shown in Figure 1. Using MRM for m/z 400.5 ±
142.0 and the appropriate LC/MS/MS conditions
described above, quinacrine could be selectively and sen-
sitively detected in plasma (Fig. 2) and brain tissue (Fig. 3)
after relatively simple sample preparation.
In vivo studies
In plasma, quinacrine concentrations with the 37.5 mg/
kg/D dose ranged from 75 to 175 ng/ml for both FVB and
CD1 strains mice and remained at this level during the 4-
week dosing interval. Once discontinued, quinacrine was
completely eliminated from plasma, with no drug detect-
able within one week. At 75 mg/kg/D quinacrine, plasma
concentrations reached >2 × those observed with the
lower dose, averaging 300 to 400 ng/ml.
Quinacrine levels in brain tissue for both mice strains
were determined to be substantially greater than those
LC/MS/MS chromatograms of quinacrine in mouse plasma Figure 2
LC/MS/MS chromatograms of quinacrine in mouse plasma
LC/MS/MS chromatograms of quinacrine in mouse brain Figure 3
LC/MS/MS chromatograms of quinacrine in mouse brain
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achieved in plasma. Similar to observations with plasma,
steady-state levels in the brain with the 37.5 mg/kg/D
dose were achieved by the end of the first week, averaging
400 to 600 ng/g brain tissue. Figure 4 characterizes the
brain tissue levels in the FBV mice. Quinacrine was unde-
tectable in brain tissue within a week after discontinuing
treatment. With the 75 mg/kg/D dose, quinacrine levels in
brain tissue were observed to be greater than 2 × those
observed with the 37.5 mg/kg/D dose, averaging 1500 ng/
g. After high-dose (75 mg/Kg/D) treatment ceased, quina-
crine levels in brain were detected for two weeks.
The analysis of liver samples showed particularly high
quinacrine levels, at many times those observed in plasma
and brain. At the end of the first week of treatment with
37.5 mg/kg/D, steady-state levels of 70 to 90 µg/g were
achieved in liver tissue in both mice strains, which
remained throughout the course of treatment. Figure 5
demonstrates the achievable liver tissue levels in FBV
mice. In contrast, the 75 mg/kg/D dosing resulted in grad-
ually increasing levels in liver tissue, rising from approxi-
mately 150 µg/g in the first week to a steady-state level of
300 to 400 µg/g by the end of the 4th week. Similarly,
spleen tissue levels in both mice strains were very ele-
vated, averaging 5 to 10 µg/g with the 37.5 mg/kg/D dose
and 40 to 100 µg/g with the 75 mg/kg/D dose. Figure 6
characterizes the spleen tissue levels of the FBV mice.
Of note, in contrast with plasma and brain tissue, in
which dose dependency was somewhat linear, increasing
quinacrine doses in spleen and liver were associated with
substantially greater tissue levels. In addition to the isola-
tion of quinacrine, numerous metabolites were identified
in all tested tissue samples (data not shown).
Discussion
The current study is the first comprehensive evaluation of
quinacrine distribution in plasma and brain tissue. Shan-
non et al. evaluated the pharmacokinetics of quinacrine in
the treatment of malaria [3]. Using a dog model, these
researchers observed quinacrine to be concentrated in the
liver and spleen, as well as muscle and lung. In the same
study, humans receiving 100 mg quinacrine three times
daily achieved maximal plasma concentrations of 100 ng/
ml. Administration of a single intravenous dose of 2 mg/
kg quinacrine in rabbits was associated with plasma levels
of 10 ng/ml [4]. The quinacrine levels we observed in
plasma are similar to those recorded from oral dosing for
malaria [3]. We observed rapid and extensive distribution
of quinacrine in brain, liver, and spleen tissue in
association with much lower plasma concentrations.
Although quinacrine was consistently observed one week
after drug discontinuation in all tissue at the 75 mg/kg/D
dose, none could be observed one week after cessation of
the 37.5 mg/kg/D doses.
Quinacrine brain levels in mice (FVB strain) administered  oral quinacrine at 37.5 or 75 mg/kg/D for 4 weeks Figure 4
Quinacrine brain levels in mice (FVB strain) administered 
oral quinacrine at 37.5 or 75 mg/kg/D for 4 weeks
Quinacrine liver levels in mice (FVB strain) administered oral  quinacrine at 37.5 or 75 mg/kg/D for 4 weeks Figure 5
Quinacrine liver levels in mice (FVB strain) administered oral 
quinacrine at 37.5 or 75 mg/kg/D for 4 weeks
Quinacrine spleen levels in mice (FVB strain) administered  oral quinacrine at 37.5 or 75 mg/kg/D for 4 weeks Figure 6
Quinacrine spleen levels in mice (FVB strain) administered 
oral quinacrine at 37.5 or 75 mg/kg/D for 4 weeks
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The concentrations we report in brain in terms of concen-
tration/gm of tissue are several-fold greater than that
shown for effective antiprion activity in ScN2a cells [2]. In
that in vitro study, the EC50 for quinacrine was 300 nM,
which approximates 120 ng/ml. We report here that
quinacrine levels in brain tissue averaged 400 to 600 ng/g
with the 37.5 mg/kg/D dose and 1500 ng/g with the 75
mg/kg/D dose, concentrations that exceed the in vitro EC50
by 3- to 10-fold.
Others have reported the antiprion function of quinacrine
in vitro, including clearance of PrPSc (5) and/or inhibition
of PrPSc formation [6]. Barret et al., who also noted the in
vitro benefit from quinacrine, found the drug to be ineffec-
tive in the animal model under the conditions employed
[1]. In contrast, some case reports in humans suggest
quinacrine to be associated with clinical improvement,
including the return of voluntary eye movement [7,8].
While the current study has confirmed brain tissue con-
centrations in excess of the reported EC50, it important to
note critical limitations in their interpretation. Quina-
crine has been determined to be highly protein-bound
[3], measured at 83–90% in older studies. Additionally,
the drug has been shown to be highly concentrated in
white blood cells with intracellular levels ranging from
9,500–18,400  µg/L with accompanying low CSF levels
(4.3–5.4 µg/L). Previous investigations confirm that it is
free drug that is microbiologically active in the treatment
of infection [9]. The brain tissue levels in the current
investigation represent the sum total of intracellular,
extracellular, protein-bound and unbound quinacrine.
Highly protein-bound agents penetrate less well between
plasma and tissue compartments, suggesting that quina-
crine would more likely be plasma-bound. However, the
results of our study strongly suggest deep brain tissue pen-
etration of quinacrine, suggesting the possible
contribution of membrane transporter proteins or other
mechanisms facilitating passage of quinacrine into brain
tissue. Considering the extensive intracellular white blood
cell concentrations achieved with quinacrine, similar
mechanisms may be responsible in actively pumping
quinacrine into these cells. Consequently, it is critical to
determine the actual free quinacrine concentrations in
both intracellular and extracellular brain tissue and to
document the relative contribution of these compart-
ments in the pathogenesis and treatment of prion disease.
Using microdialysis probes, Mindermann and colleagues
[10] evaluated the penetration of rifampin into cerebral
extracellular space, brain tumor, perifocal, and normal
brain tissue. The findings confirmed consistent cerebral
extracellular space concentrations, but remarkably differ-
ent rifampin brain tissue levels, particularly concentrating
in brain tumor tissue. Considering the pathogenesis of
prion disease, heterogeneity of brain tissue concentrations
may impact similarly the efficacy of quinacrine or other
agents. Our results strongly suggest that similar microdial-
ysis experiments take place with quinacrine to clarify the
distribution characteristics of this agent.
In addition to steady-state levels of quinacrine, we
observed a number of quinacrine metabolites in all tissue
samples studied, which raises the possibility that these
metabolites may have in vitro antiprion activity similar to
or greater than that of the parent compound. These tests
warrant further evaluation.
Conclusions
Based upon its oral bioavailability, favorable tissue distri-
bution characteristics, and in vitro activity, quinacrine may
be a useful agent in the treatment of prion disease. How-
ever, more detailed tissue distribution analyses linked
with the critical sites of prion action are warranted.
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